Q-omics provides the consensus-scored LRBA profile across patient tissues and cancer cell-line models. LRBA expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRBA is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LRBA protein abundance shows 23,756 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, and BRCA as cancer lineages where LRBA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRBA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRBA survival associations across molecular data types. LRBA RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRBA RNA expression–survival associations across cancer types. High LRBA expression shows unfavorable associations in CESC, but favorable associations in KIRC, ACC, BRCA, HNSC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LRBA RNA expression.
This table summarizes LRBA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LRBA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRBA shows lower tumor expression in KIRC and KICH and higher tumor expression in BRCA, STAD, LUAD and LIHC. The KIRC box plot shows higher LRBA RNA expression in normal versus tumor tissue (log2 FC = −0.938, t-test p < 0.001).
This table shows molecular features associated with LRBA in patient tissues and cancer cell lines. In patient samples, LRBA shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LRBA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
